Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Cash from Investing Activities (2018 - 2021)

Regen BioPharma (RGBPP) has disclosed Cash from Investing Activities for 5 consecutive years, with $195000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Cash from Investing Activities changed N/A to $195000.0 in Q3 2021 year-over-year; TTM through Dec 2022 was $495000.0, a 0.0% change, with the full-year FY2022 number at $25000.0, down 94.95% from a year prior.
  • Cash from Investing Activities was $195000.0 for Q3 2021 at Regen BioPharma, down from $300000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $300000.0 in Q2 2021 to a low of -$5741.0 in Q2 2018.